Related Experiment Video
Updated: Aug 7, 2026

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
Published on: March 14, 2019
Mesigyna once-a-month combined injectable contraceptive: experience in Latin America
S Bassol1, M C Cravioto, M Durand
1Centro de Investigacion Biomedica Universidad, Autonoma de Coahuila, Mexico. sbassol@hotmail.com
Abstract:
A phase III clinical study was carried out among 534 fertile Latin American women to evaluate cycle control, side effects, and contraceptive efficacy of a once-a-month combined injectable, Mesigyna, consisting of 50 mg norethisterone enanthate and 5 mg estradiol valerate. The pregnancy rate at 1 year was 0 per 100 woman-years for a total experience of 4688 woman-months. The overall discontinuation rate at one year was 17.9%. Discontinuation rate for bleeding problems was 5.1%. The Colombian women had a significant increase (p <0.001) in bleeding problems compared to other countries. The discontinuation rate for amenorrhea was 1.1%. There were no significant differences between the groups regarding discontinuation for other medical or non-medical reasons. Mean weight gain after one year of use was 1.02 kg. Mesigyna is an appropiate once-a-month injectable contraceptive for Latin American women since it is highly effective and its perception of normal menstrual bleeding is of importance in the Latin American population.
Related Concept Videos
Birth Control Methods
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Oral Drug Delivery Systems: Continuous-Release Systems
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Intrauterine Drug Delivery Systems

